Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-Based Steroid Avoidance in African American Kidney Transplant Recipients
NCT00189202Phase 3Completed
- Sponsor
- University of Michigan
- Start
- Aug 2004
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sirolimus in kidney transplant rejection (2 arms), sponsored by University of Michigan. Primary endpoints: Cumulative One-year Acute Rejection Rates at 12 months, One-year Graft Survival at 12 months and 1 more. Started Aug 2004; status: completed.
02
Drugs
sirolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00189202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189202.